Aldoxorubicin

Drug Profile

Aldoxorubicin

Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - CytRx Corporation

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator KTB Tumorforschungs
  • Developer CytRx Corporation
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Hydrazines; Maleimides; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Soft tissue sarcoma; Pancreatic cancer; Glioblastoma; Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Osteosarcoma; Solid tumours

Most Recent Events

  • 01 Dec 2016 CytRx completes a phase II trial in Glioblastoma in USA (NCT02014844)
  • 29 Nov 2016 Updated adverse events and efficacy data from a phase III trial in Soft tissue sarcoma released by CytRx Corporation
  • 11 Nov 2016 Updated interim efficacy and adverse events data from a phase I/II trial in Soft tissue sarcoma released by CytRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top